Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Biofrontera Inc. (BFRI)

Biofrontera Q2 revenue rises 33% to $12.0 million; net loss narrows to $0.6 million

Positive Impact 3 of 5 earnings Written later

Biofrontera reported second-quarter 2026 net product revenue of $12.0 million, up 32.9% from a year earlier, and a net loss of $0.6 million, compared with $5.3 million in the prior-year quarter. The company attributed its gross margin rise to 80% from 71% mainly to a lower Ameluz cost structure following its October 2025 strategic transaction with Biofrontera AG. The filing also notes an ITC exclusion order on its RhodoLED XL lamp, effective July 7, 2026, and cash of $4.7 million as of June 30, 2026.

Key points

  • Net product revenue was $12.0 million for Q2 2026, up $3.0 million, or 32.9%, from $9.0 million.
  • Gross margin was 80% versus 71%; net loss was $0.6 million, or $(0.05) per share, versus $5.3 million, or $(0.57) per share.
  • An ITC exclusion order on the RhodoLED XL lamp took effect July 7, 2026; the company says it is pursuing a remediation plan for a modified lamp.
  • Cash and cash equivalents were $4.7 million at June 30, 2026; total stockholders' equity was $6.0 million, down from $10.5 million at December 31, 2025.

The filing

CompanyBiofrontera Inc. (BFRI)
Form8-K, current report
Filed with the SECAug 13, 2026, 9:00 AM ET
Accession number0001493152-26-037610

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.